Revlimid
Term · Oncology and biomedicine · MLC-T-ONC-007417
A drug that is similar to thalidomide and is used alone or with other drugs to treat adults with certain types of follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, multiple myeloma, or anemia caused by certain types of myelodysplastic syndromes. It is also being studied in the treatment of other conditions and types of cancer. Revlimid may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. Revlimid is a type of antiangiogenesis agent and a type of immunomodulating agent. Also called CC-5013 and lenalidomide.
| Identifier | MLC-T-ONC-007417 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | CC-5013; lenalidomide |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-007417",
"term": "Revlimid",
"field": "Oncology and biomedicine",
"definition": "A drug that is similar to thalidomide and is used alone or with other drugs to treat adults with certain types of follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, multiple myeloma, or anemia caused by certain types of myelodysplastic syndromes. It is also being studied in the treatment of other conditions and types of cancer. Revlimid may help the immune system kill abnormal blood cells or cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. Revlimid is a type of antiangiogenesis agent and a type of immunomodulating agent. Also called CC-5013 and lenalidomide.",
"synonyms": [
"CC-5013",
"lenalidomide"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/revlimid/"
}
Record 14,428 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.